Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions

Bayry, Jagadeesh; Ahmed, Eisha; Toscano-Rivero, Diana; Vonniessen, Nicholas; Genest, Geneviève; Cohen, Casey; Dembele, Marieme; Kaveri, Srini V.; Mazer, Bruce

doi:10.1016/j.jaip.2023.04.002

Cited by 23 publications

(7 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunosuppression property of IVIg is evident from its ability to ameliorate ITP [ 19 , 31 , 63 , 64 ]. We have previously shown that ambient cold exposure inducedimmunosuppression through an IVIg-like pathway in mice, which could be typically induced in wild-type but not in P-selectin deficient ( Selp −/− ) mutant mice [ 18 ].…”

Section: Resultsmentioning

confidence: 99%

“…In this study, we aim to compare restraint-stress-induced immunosuppression with two other established models: intravenous immunoglobulin (IVIg) administration and ambient cold exposure [ 18 , 19 ]. IVIg is a mixture of human antibodies and a clinically used drug in immunoglobulin therapy to treat inflammatory and autoimmune diseases, such as immune thrombocytopenia (ITP), Kawasaki disease, systemic lupus erythematosus, dermatomyositis, neurologic disorders, and even COVID-19 infections [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ]. IVIg-induced immunosuppression refers to the suppression of the immune system following the administration of IVIg, which contains high levels of antibodies; however, its mechanism is still not fully understood [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Restraint Stress-Induced Immunosuppression Is Associated with Concurrent Macrophage Pyroptosis Cell Death in Mice

Li,

Munalisa,

Lee

et al. 2023

IJMS

View full text Add to dashboard Cite

Psychological stress is widely acknowledged as a major contributor to immunosuppression, rendering individuals more susceptible to various diseases. The complex interplay between the nervous, endocrine, and immune systems underlies stress-induced immunosuppression. However, the underlying mechanisms of psychological-stress-induced immunosuppression remain unclear. In this study, we utilized a restraint stress mouse model known for its suitability in investigating physiological regulations during psychological stress. Comparing it with cold exposure, we observed markedly elevated levels of stress hormones corticosterone and cortisol in the plasma of mice subjected to restraint stress. Furthermore, restraint-stress-induced immunosuppression differed from the intravenous immunoglobulin-like immunosuppression observed in cold exposure, with restraint stress leading to increased macrophage cell death in the spleen. Suppression of pyroptosis through treatments of inflammasome inhibitors markedly ameliorated restraint-stress-induced spleen infiltration and pyroptosis cell death of macrophages in mice. These findings suggest that the macrophage pyroptosis associated with restraint stress may contribute to its immunosuppressive effects. These insights have implications for the development of treatments targeting stress-induced immunosuppression, emphasizing the need for further investigation into the underlying mechanisms.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Restraint Stress-Induced Immunosuppression Is Associated with Concurrent Macrophage Pyroptosis Cell Death in Mice

Li,

Munalisa,

Lee

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…IVIg is also known to inhibit the activation of innate immune cells [macrophage/monocyte lineage cells and dendritic cells (DCs)] through induction of Fas-mediated apoptosis and triggering the production of counter-regulatory cytokines. In addition, IVIg contains neutralizing antibodies that bind to cytokines produced by innate immune cells ( 111 ). It also modifies both activating and inhibitory signaling through Fcγ receptors ( 111 ).…”

Section: Immunomodulating Agents Utilized For Autoimmune/autoinflamma...mentioning

confidence: 99%

“…In addition, IVIg contains neutralizing antibodies that bind to cytokines produced by innate immune cells ( 111 ). It also modifies both activating and inhibitory signaling through Fcγ receptors ( 111 ). Such effects of IVIg on Fcγ receptors are attributed to α2,6-sialic acid portion of immunoglobulins that exert actions via the DC-SIGN signaling in murine models ( 112 , 113 ).…”

Section: Immunomodulating Agents Utilized For Autoimmune/autoinflamma...mentioning

confidence: 99%

“…However, it is unclear whether the same actions take place in human cells. IVIg has also been shown to suppress B cell activation/proliferation by agonistic binding to inhibitory cell surface receptors on B cells ( 111 ). Antibodies contained in IVIg have also been shown to directly neutralize pathogenic autoantibodies ( 111 ).…”

Section: Immunomodulating Agents Utilized For Autoimmune/autoinflamma...mentioning

confidence: 99%

See 1 more Smart Citation

Autism spectrum disorder and a possible role of anti-inflammatory treatments: experience in the pediatric allergy/immunology clinic

Jyonouchi

2024

Front. Psychiatry

View full text Add to dashboard Cite

Autism spectrum disorder (ASD1) is a behaviorally defined syndrome encompassing a markedly heterogeneous patient population. Many ASD subjects fail to respond to the 1st line behavioral and pharmacological interventions, leaving parents to seek out other treatment options. Evidence supports that neuroinflammation plays a role in ASD pathogenesis. However, the underlying mechanisms likely vary for each ASD patient, influenced by genetic, epigenetic, and environmental factors. Although anti-inflammatory treatment measures, mainly based on metabolic changes and oxidative stress, have provided promising results in some ASD subjects, the use of such measures requires the careful selection of ASD subjects based on clinical and laboratory findings. Recent progress in neuroscience and molecular immunology has made it possible to allow re-purposing of currently available anti-inflammatory medications, used for autoimmune and other chronic inflammatory conditions, as treatment options for ASD subjects. On the other hand, emerging anti-inflammatory medications, including biologic and gate-keeper blockers, exert powerful anti-inflammatory effects on specific mediators or signaling pathways. It will require both a keen understanding of the mechanisms of action of such agents and the careful selection of ASD patients suitable for each treatment. This review will attempt to summarize the use of anti-inflammatory agents already used in targeting ASD patients, and then emerging anti-inflammatory measures applicable for ASD subjects based on scientific rationale and clinical trial data, if available. In our experience, some ASD patients were treated under diagnoses of autoimmune/autoinflammatory conditions and/or post-infectious neuroinflammation. However, there are little clinical trial data specifically for ASD subjects. Therefore, these emerging immunomodulating agents for potential use for ASD subjects will be discussed based on preclinical data, case reports, or data generated in patients with other medical conditions. This review will hopefully highlight the expanding scope of immunomodulating agents for treating neuroinflammation in ASD subjects.

show abstract

Advancing Aggregation‐Induced Emission‐Derived Biomaterials in Viral, Tuberculosis, and Fungal Infectious Diseases

Wang,

et al. 2024

Aggregate

View full text Add to dashboard Cite

Contagious diseases caused by different types of highly contagious pathogens, such as SARS‐CoV‐2, monkeypox virus, Mycobacterium tuberculosis, and human immunodeficiency virus, could trigger global outbreaks and bring a huge public health burden. Advanced diagnostic, therapeutic, and preventive strategies are urgently needed to deal with the epidemic of contagious diseases. Aggregation‐induced emission (AIE) has emerged as one of the promising candidates that exhibit tunable photophysical properties, high biocompatibility, exceptional photostability, and a distinguishing aggregation‐enhanced fluorescence. As a result, they offer effective strategies for the diagnosis, treatment, and prevention of contagious diseases. This review systematically outlined the latest research progress of AIE‐based biomaterials and mechanisms in contagious diseases. The versatility of AIE molecules, as well as highly efficient fluorescence properties, has the potential to offer innovative strategies to combat these health challenges. Thanks to recent advances in materials science and a better understanding of aggregation‐induced emission luminogens (AIEgens), AIEgens have great potential to provide better solutions for the treatment, detection, and prevention of contagious diseases. By reviewing state‐of‐the‐art methods for the killing, detection, and prevention of contagious agents and highlighting promising technological developments, this outlook aims to promote the development of new means for the prevention and control of emerging, re‐emerging, and major contagious diseases as well as further research and development activities in this critical area of research.

show abstract

Intravenous Immunoglobulin: Mechanism of Action in Autoimmune and Inflammatory Conditions

Cited by 23 publications

References 142 publications

Restraint Stress-Induced Immunosuppression Is Associated with Concurrent Macrophage Pyroptosis Cell Death in Mice

Restraint Stress-Induced Immunosuppression Is Associated with Concurrent Macrophage Pyroptosis Cell Death in Mice

Autism spectrum disorder and a possible role of anti-inflammatory treatments: experience in the pediatric allergy/immunology clinic

Advancing Aggregation‐Induced Emission‐Derived Biomaterials in Viral, Tuberculosis, and Fungal Infectious Diseases

Contact Info

Product

Resources

About